Organization
University of Michigan, Ann Arbor, United States of America
3 abstracts
Abstract
BASELINE CHARACTERISTICS OF SYSTEMIC SCLEROSIS PATIENTS WITH BORDERLINE MEAN PULMONARY ARTERY PRESSURE: POST-HOC ANALYSIS FROM THE DETECT STUDY Org: University of Michigan, Ann Arbor, United States of America, University Hospital Zurich, Zurich, Switzerland, Royal Free Hospital, London, United Kingdom, University Hospital Heidelberg, Heidelberg, Germany, Medical University of Vienna, Vienna, Austria,
Abstract
BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS IN SUBJECTS WITH ILD IN A PHASE 2 STUDY TO EVALUATE EFFICACY, SAFETY, AND TOLERABILITY OF MT-7117 IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSISOrg: University of Michigan, Ann Arbor, United States of America, Hospital Universitario 12 de Octubre, Madrid, Spain, Stanford University School of Medicine, Stanford, United States of America, University College London and Royal Free Hospital, London, United Kingdom, IRCCS San Raffaele University Hospital, Milan, Italy,
Abstract
ABATACEPT IN EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS— RESULTS OF A PHASE 2 INVESTIGATOR-INITIATED, MULTICENTER, DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIALOrg: University of Michigan, Ann Arbor, United States of America, Univ of Toronto, Toronto, Canada, Stanford Univ, Palo Alto, United States of America, UCL, London, United Kingdom, Univ of Minnesota, Minneapolis, United States of America,